20-F: Zepp Health Corporation Files 20-F, Details Technology Transfer and Corporate Structure

Zepp Health Corporation's 20-F filing reveals a technology transfer agreement and provides insights into its corporate structure and financial performance.

Summary

• Zepp Health Corporation, a Cayman Islands holding company, conducts its operations in China through PRC subsidiaries and VIEs.
• A technology transfer agreement was entered into on September 28, 2023, transferring ownership of Huangshan 2/2S proprietary technology from Hefei Huami Micro-electronics Co., Ltd. to Whale Microelectronics Co., Ltd.
• The transfer fee for the technology is RMB [***] excluding tax, with payment installments scheduled over 36 months.
• The company relies on contractual arrangements with VIEs, which poses risks related to control and regulatory compliance in China.
• Zepp Health faces uncertainties regarding PRC laws and regulations, including those related to data security and overseas offerings.
• The company's ADSs may be prohibited from trading in the U.S. under the Holding Foreign Companies Accountable Act (HFCAA) if PCAOB cannot inspect auditors in China.
• The company has established stringent controls and procedures for cash flows within its organization.
• The company's operations are subject to permissions required from PRC authorities.
• The company's financial data, including revenue, cost of revenue, and operating expenses, are detailed in the filing.
• The company's selected consolidated financial data for 2019-2023 is provided, showing a decline in revenue in recent years.
• The company's condensed consolidating schedule of financial position for the VIEs and other entities as of the dates presented is provided.
• The company faces various risks related to its business, corporate structure, and operating in China, which could affect its financial performance and ADS value.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positives like the technology transfer and established cash management, the declining revenue, operating losses, and regulatory risks weigh heavily, resulting in a slightly negative sentiment.

Positives

• The company has established stringent controls and procedures for cash flows within its organization.
• The company's operations are subject to permissions required from PRC authorities.
• The company has a clawback policy in place for executive compensation in case of financial restatements.

Negatives

• The company's revenue has declined, with VIEs contributing 39.8% of total revenue in 2023.
• The company faces risks related to VIE structure, PRC regulations, and potential delisting under the HFCAA.

Risks

• The company relies on contractual arrangements with VIEs, which poses risks related to control and regulatory compliance in China.
• Zepp Health faces uncertainties regarding PRC laws and regulations, including those related to data security and overseas offerings.
• The company's ADSs may be prohibited from trading in the U.S. under the Holding Foreign Companies Accountable Act (HFCAA) if PCAOB cannot inspect auditors in China.
• Any deterioration of the company's relationship with Xiaomi or reduction of sales of Xiaomi Wearable Products could have a significant adverse effect on operating results.
• The company collects, stores, processes and uses personal information and other user data, which subjects the company to laws, governmental regulations and other legal obligations related to privacy, information security and data protection, and any actual or perceived failure to comply with such legal obligations could harm the company's brand and business.

Future Outlook

The company expects sales of Amazfit and Zepp branded products to increasingly contribute to total revenues going forward. The company currently intends to retain available funds and any future earnings to operate and expand its business.

Industry Context

The smart wearables market is highly competitive with numerous participants, including specialized consumer electronics companies, large broad-based consumer electronics companies, traditional health and fitness companies, and traditional watch companies.

Comparison to Industry Standards

• The document mentions competitors like Fitbit, Garmin, Huawei, Apple, and Samsung, but does not provide a detailed comparison of Zepp Health's results against specific industry benchmarks.
• The document does not provide a detailed comparison of Zepp Health's results against specific industry benchmarks.

Related Party Transactions

• The company has a business cooperation agreement with Xiaomi for the sale of Xiaomi Wearable Products.
• The company purchased raw materials from Whale Microelectronics Co., Ltd., a subsidiary of Jiangsu Yitong, an affiliate of the company.
• The company transferred the technologies related to Huangshan-2/2S smart wearable chips to Whale Microelectronics Co., Ltd., a subsidiary of Jiangsu Yitong, an affiliate of the company.

Stakeholder Impact

• Shareholders face risks related to the VIE structure, PRC regulations, and potential delisting under the HFCAA.
• The company's ability to distribute earnings to shareholders is limited by PRC regulations.
• The company's performance and strategic decisions impact employees, customers, and suppliers.

Next Steps

• The company will continue to develop international markets, especially Europe and the U.S.
• The company plans to continue to leverage strategic relationships with existing strategic partners to grow its business while pursuing new relationships with additional strategic partners.
• The company plans to utilize the laboratory achievements to further develop its products and services in building a comprehensive health and fitness ecosystem.

Key Dates

Keywords

Zepp Health, Technology Transfer, VIE Structure, Financial Results, Risk Factors, PCAOB, HFCAA, Xiaomi, China Regulations, Financial Metrics